company background image
PBP logo

Probiotec ASX:PBP Stock Report

Last Price

AU$2.98

Market Cap

AU$242.3m

7D

0%

1Y

11.6%

Updated

18 Jun, 2024

Data

Company Financials +

Probiotec Limited

ASX:PBP Stock Report

Market Cap: AU$242.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

PBP Stock Overview

Engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. More details

PBP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance2/6
Financial Health4/6
Dividends1/6

Rewards

Trading at 48.4% below our estimate of its fair value

Revenue is forecast to grow 6.67% per year

Risk Analysis

Profit margins (3.9%) are lower than last year (7.2%)


My Notes

Capture your thoughts, links and company narrative

Probiotec Limited Competitors

Vita Life Sciences

ASX:VLS

AU$101.5m

Vitura Health

ASX:VIT

AU$44.2m

ECS Botanics Holdings

ASX:ECS

AU$19.3m

Neuren Pharmaceuticals

ASX:NEU

AU$1.8b

Price History & Performance

Summary of share price highs, lows and changes for Probiotec
Historical stock prices
Current Share PriceAU$2.98
52 Week HighAU$3.03
52 Week LowAU$2.14
Beta0.47
1 Month Change2.05%
3 Month Change6.81%
1 Year Change11.61%
3 Year Change39.91%
5 Year Change91.03%
Change since IPO158.01%

Recent News & Updates

Recent updates

Probiotec (ASX:PBP) Is Increasing Its Dividend To A$0.03

Feb 26
Probiotec (ASX:PBP) Is Increasing Its Dividend To A$0.03

Probiotec (ASX:PBP) Has Affirmed Its Dividend Of AU$0.02

Feb 28
Probiotec (ASX:PBP) Has Affirmed Its Dividend Of AU$0.02

Shareholder Returns

PBPAU PharmaceuticalsAU Market
7D0%0.6%0.2%
1Y11.6%-4.9%8.4%

Return vs Industry: PBP underperformed the Australian Pharmaceuticals industry which returned 63.2% over the past year.

Return vs Market: PBP exceeded the Australian Market which returned 6.1% over the past year.

Price Volatility

Is PBP's price volatile compared to industry and market?
PBP volatility
PBP Average Weekly Movement1.8%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.4%
10% least volatile stocks in AU Market2.9%

Stable Share Price: PBP has not had significant price volatility in the past 3 months.

Volatility Over Time: PBP's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996n/aWes Stringerwww.probiotec.com.au

Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials.

Probiotec Limited Fundamentals Summary

How do Probiotec's earnings and revenue compare to its market cap?
PBP fundamental statistics
Market capAU$242.34m
Earnings (TTM)AU$8.69m
Revenue (TTM)AU$221.22m

27.9x

P/E Ratio

1.1x

P/S Ratio

Is PBP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PBP income statement (TTM)
RevenueAU$221.22m
Cost of RevenueAU$154.96m
Gross ProfitAU$66.25m
Other ExpensesAU$57.57m
EarningsAU$8.69m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin29.95%
Net Profit Margin3.93%
Debt/Equity Ratio52.5%

How did PBP perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

65%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/18 03:20
End of Day Share Price 2024/06/18 00:00
Earnings2023/12/31
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Probiotec Limited is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew TangMorgans Financial Limited
James FiliusMorgans Financial Limited
Filius JamesMorgans Financial Limited